- Home
- ABP vs NEUP Comparison
ABP vs NEUP Comparison
Compare ABP & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABP
- NEUP
- Stock Information
- Founded
- ABP 2004
- NEUP 1996
- Country
- ABP United States
- NEUP United States
- Employees
- ABP N/A
- NEUP N/A
- Industry
- ABP Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- ABP Health Care
- NEUP
- Exchange
- ABP Nasdaq
- NEUP Nasdaq
- Market Cap
- ABP 15.5M
- NEUP 12.7M
- IPO Year
- ABP N/A
- NEUP N/A
- Fundamental
- Price
- ABP $0.21
- NEUP $7.10
- Analyst Decision
- ABP Strong Buy
- NEUP Strong Buy
- Analyst Count
- ABP 1
- NEUP 1
- Target Price
- ABP $4.00
- NEUP $21.00
- AVG Volume (30 Days)
- ABP 5.7M
- NEUP 24.5K
- Earning Date
- ABP 08-18-2025
- NEUP 08-15-2025
- Dividend Yield
- ABP N/A
- NEUP N/A
- EPS Growth
- ABP N/A
- NEUP N/A
- EPS
- ABP N/A
- NEUP 0.00
- Revenue
- ABP $183,000.00
- NEUP $15,662,715.00
- Revenue This Year
- ABP N/A
- NEUP N/A
- Revenue Next Year
- ABP N/A
- NEUP N/A
- P/E Ratio
- ABP N/A
- NEUP $2.29
- Revenue Growth
- ABP 88.66
- NEUP N/A
- 52 Week Low
- ABP $0.15
- NEUP $2.90
- 52 Week High
- ABP $11.19
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- ABP N/A
- NEUP N/A
- Support Level
- ABP N/A
- NEUP N/A
- Resistance Level
- ABP N/A
- NEUP N/A
- Average True Range (ATR)
- ABP 0.00
- NEUP 0.00
- MACD
- ABP 0.00
- NEUP 0.00
- Stochastic Oscillator
- ABP 0.00
- NEUP 0.00
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.